



Cynvec LLCSM to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008

New York, NY, (December 2, 2008) – Cynvec LLC, a privately-held biopharmaceutical company focused on developing novel cancer therapies that harness the apoptotic ability of the Sindbis viral vector, today announced that executive management will participate in the NYSSA 12th Annual Biotech and Specialty Pharma Conference in New York on December 2, 2008. The conference is being held at 1177 Avenue of the Americas, 2nd floor, New York City. Frank D. Stonebanks, President and Chief Executive Officer, is scheduled to present an overview of the company at 1:00 p.m. ET today.

The presentation will be webcast live and archived for 30 days following the presentation on the company's website at www.cynvec.com.

About Cynvec LLC

Cynvec was founded in 2004 and is a development stage biotech company based in New York City. The Company is focused on developing Sindbis-based viral vectors as standalone oncolytic therapeutics, delivery systems for monoclonal antibodies and cytokines as well as cancer diagnostic products. The Sindbis vector system, originally developed at NYU School of Medicine, represents a unique, patented platform technology for numerous commercial applications. The company is developing therapies to treat a number of tumor types, including ovarian, pancreatic, GI, liver, colorectal, and other cancers where the laminin receptor is overexpressed. The Company's lead product, CYN 101, is in late pre-clinical development, and has shown statistically significant survival rates in both ovarian and pancreatic cancer models. Further information on Cynvec can be found at www.cynvec.com.

Contact:

Gregory Gin, Invigorate Communications
908-376-7737
ggin@invigoratepr.com